ACRS

Aclaris Therapeutics, Inc. (ACRS) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company operates as a single reportable segment, generating revenue primarily through licensing agreements and contract research services. As of the reporting date, the company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Revenue Breakdown (YTD 2026): Licensing revenue was $2.73 million, and Contract research revenue was $0.89 million.

Expense Breakdown (YTD 2026): Research and Development (R&D) expenses were $33.72 million, General and Administrative (G&A) expenses were $12.79 million, and Licensing expenses were $2.63 million.

Material Changes vs. Prior Period

• Revenue: Total revenue increased by $0.39 million (12%) year-over-year for the six months ended June 30, 2026, driven primarily by higher royalties from the Eli Lilly and Sun Pharma license agreements. Contract research revenue remained relatively flat.
• Net Loss: Net loss increased by $10.82 million (35%) year-over-year. This was primarily due to a $10.69 million increase in R&D expenses.
• R&D Expenses: Significant increases were observed in specific programs:
  • ATI-052: Expenses rose by $6.04 million due to manufacturing costs and Phase 1b clinical trials.
  • ATI-9494: Expenses rose by $3.73 million due to manufacturing and preclinical toxicity studies.
  • Discovery: Expenses rose by $1.99 million due to increased investment in JAK-sparing ITK inhibitors.
• Contingent Consideration: The revaluation loss decreased by $1.50 million year-over-year, attributed to changes in the probability of success for certain candidates and lower discount rates applied in the prior year.
• Financing Activity: In March 2026, the company raised $57.9 million net from an at-the-market (ATM) equity offering. In July 2026 (subsequent event), an additional $40.2 million gross was raised via the ATM facility.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($170.6 million) are sufficient to fund operations for more than 12 months from the filing date. However, the company has an accumulated deficit of $1.0 billion and expects to incur significant losses in the foreseeable future.
• Clinical Pipeline Updates:
  • Bosakitug (ATI-045): Phase 2 trial in atopic dermatitis initiated in June 2025; top-line data expected in Q4 2026.
  • ATI-052: Positive Phase 1a results announced in April 2026. Phase 1b trials in atopic dermatitis and asthma initiated in early 2026; data expected in H2 2026. Phase 2b in asthma planned for Q4 2026.
  • Modzatinib: Phase 2a in atopic dermatitis completed in July 2025 with positive results. Phase 2b basket study in lichen planus planned for initiation in Q4 2026.
  • ATI-9494: IND application expected in Q4 2026.
• Risks: The company faces risks related to the uncertainty of clinical trial outcomes, the ability to raise additional capital on acceptable terms, and the potential need to curtail operations if funding is insufficient. Macroeconomic factors such as inflation and geopolitical tensions may also impact the business.
• Contingent Liabilities: The company has a contingent consideration liability of $11.3 million related to the Confluence acquisition, subject to regulatory and commercial milestones.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $170.6 million cash position against the accelerating R&D burn rate ($33.7M in H1 2026) to confirm the >12 month liquidity assertion.
• ATI-052 Progress: Monitor the upcoming Phase 1b data (H2 2026) and the initiation of the Phase 2b asthma trial (Q4 2026) as key value drivers.
• Equity Dilution: Note the recent ATM sales (18.4M shares in March 2026 and 7.3M shares in July 2026) and the outstanding warrants (3M shares unexercised) which may impact future share count.
• Licensing Revenue Quality: A significant portion of licensing revenue ($2.4M in H1 2026 from Lilly) is payable to third parties; verify the net economic benefit to Aclaris.
• Contingent Consideration: Track the $11.3 million liability and the assumptions (probability of success 21-40%) used to value it, as changes could materially impact net income.